Related Experiment Video
Updated: May 24, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Paraneoplastic neurologic syndrome: A practical approach.
1Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Annals of Indian Academy of Neurology
|March 14, 2012
Summary
Paraneoplastic neurological syndromes (PNS) are rare autoimmune disorders linked to cancer, often appearing before cancer diagnosis. Early detection and treatment of cancer and PNS, including immunotherapy, improve patient outcomes.
Area of Science:
- Neurology
- Oncology
- Immunology
Background:
- Paraneoplastic neurological syndromes (PNS) are rare autoimmune disorders associated with cancer.
- PNS can manifest before the primary cancer is detected.
- Onconeural antibodies play a crucial role in diagnosing and managing PNS.
Purpose of the Study:
- To highlight the diagnostic and management strategies for paraneoplastic neurological syndromes.
- To emphasize the importance of investigating onconeural antibodies in suspected PNS cases.
- To discuss the role of cancer detection, immunotherapy, and supportive care in managing PNS.
Main Methods:
- Review of literature on paraneoplastic neurological syndromes and onconeural antibodies.
- Discussion of diagnostic approaches including antibody testing and cancer screening.
- Overview of treatment modalities such as immunotherapy and supportive care.
Main Results:
- Onconeural antibodies are specific to the underlying malignancy and aid in diagnosis.
- PNS can occur in 30-40% of cases without detectable antibodies.
- Immunotherapy, particularly for cell membrane-associated antibodies, is effective.
- Cancer detection and treatment are critical components of PNS management.
Conclusions:
- A high index of clinical suspicion is essential for early diagnosis of PNS.
- Comprehensive investigation of onconeural antibodies is vital.
- Integrated treatment involving cancer care, immunotherapy, and supportive therapy improves outcomes.
Related Concept Videos
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...